Prosthetic Heart Valve Market, By Position Type (Aortic Valve, Mitral Valve, and Others), By Valve Type (Mechanical Valves, Tissue Valves, and Transcatheter Valves), By End User (Hospitals, Ambulatory Surgical Centres, Catheterization Laboratory, and Others), , By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

Published In : Mar 2024

Code : CMI69

Pages :155

Formats :

Excel and PDF

Industry : Medical Devices

Regional Analysis

Prosthetic Heart Valve Market Regional Insights Regional Insights

To learn more about this report, request sample copy

The North American region has remained the dominant market for prosthetic heart valves globally and is projected to hold 45.9% of the market share in 2024. This can be attributed to cutting-edge research and strong presence of industry leaders in the region. The U.S. in particular houses the headquarters of major players like Edwards Lifesciences, Medtronic, and Abbott that continue to invest heavily in R&D for development of innovative valve designs. Furthermore, favorable reimbursement policies for transcatheter aortic valve replacement (TAVR) procedures in the country ensure higher adoption rates of newer valve technologies.

On the pricing front, North America is able to command a small premium over other regions due to the brand reputation of valves manufactured by domestic companies. However, with rising healthcare costs, payers are pushing for more affordable options. This has led companies to rationalize portfolios by discontinuing older surgical valve models in favor of their latest transcatheter alternatives. Given the large patient pool in the US, even a small decline in average selling price can have significant impact on overall revenues for firms.

The Asia Pacific region has emerged as the fastest growing marketplace for prosthetic heart valves globally. Rapid modernization of healthcare infrastructure and increase in per capita incomes are propelling growth. Governments in various APAC countries have implemented national health insurance plans to ensure wider access to cardiac treatments. However, with a higher proportion of rheumatic heart disease cases compared to developed markets, the preference still remains for cheaper mechanical valves in this region rather than tissue/bioprosthetic alternatives.